Eli Lilly And Co. (LLY) became the talk onFriday by briefly becoming the first healthcare company in the world to hit a
$1 trillion market value.
Their shares shot up during morning tradingbefore settling down a bit, but this achievement really highlights the
impressive momentum behind their blockbuster drugs for weight loss and
diabetes.
So far this year, Lilly's stock has gone upover 36 percent, thanks to the skyrocketing demand for their drugs Mounjaro and
Zepbound. Mounjaro pulled in $6.52 billion in revenue for the third quarter
more than double what they made last year while Zepbound brought in $3.59
billion, a jump of 184 percent.
Lilly is gearing up to launch an oralversion next year, which could make these treatments even more available.
Now, they've joined Berkshire Hathaway asthe second non-tech U.S. company to enter the trillion-dollar club. Their swift
ascent showcases the explosive growth in the weight-loss drug market, which
could surpass $150 billion by the 2030s.
Even though they're facing some challenges,rival Novo Nordisk is still a tough competitor, and Pfizer is diving deeper
into the market after acquiring Metsera, a developer of obesity drugs.
As for now Eli Lilly is at the forefront ofa booming industry.